Tetraspecific octameric binders and antibodies to Clostridium difficile toxin A and toxin B for the treatment of Clostridium difficile infection

摘要

Novel antibody-based binders derived from human immunoglobulins and camelid immunoglobulins have been described. These binders recognize and specifically bind to Clostridium difficile toxin A and / or toxin B, and in some cases, exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binder includes camelid VHH peptide monomers, a group of linked VHH peptide monomers, a VHH peptide monomer bound to the Fc domain of an antibody, and a single amount of VHH peptide bound to an IgG antibody Contains the body. [Selection] Figure 8